{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:24:08Z","timestamp":1740140648401,"version":"3.37.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>We examined the concordance of genetic mutations between pretreatment tumor tissue and posttreatment circulating tumor DNA (ctDNA) in patients with metastatic squamous cell carcinoma of the anal canal (SCCA) and assessed the impact of therapy on this concordance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed next-generation sequencing reports from pretreatment tumor tissue and posttreatment ctDNA in 11 patients with metastatic SCCA treated at Vanderbilt University Medical Center between 2017 and 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the mutations identified in posttreatment ctDNA, 34.5% were also found in pretreatment tumor tissue, while 47.6% of pretreatment tumor tissue mutations were found in posttreatment ctDNA. Four patients had preservation of potentially actionable mutations in both pretreatment tissue and posttreatment ctDNA, while 7 patients had newly identified mutations in posttreatment ctDNA that were not present in pretreatment tumor tissue.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with SCCA demonstrate a high degree of temporal mutational heterogeneity. This supports the hypothesis that ctDNA can serve as a real-time tracking mechanism for solid tumors\u2019 molecular evolution in response to therapy. Our findings highlight the potential of ctDNA in identifying emerging actionable mutations, supplementing information from tissue-based genomic assessments. Further research, ideally with larger and multi-institutional cohorts, is needed to validate our findings in this relatively rare tumor type.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad326","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T15:08:46Z","timestamp":1702739326000},"page":"e475-e486","source":"Crossref","is-referenced-by-count":0,"title":["Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-0561","authenticated-orcid":false,"given":"Michael","family":"LaPelusa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Cann","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen K","family":"Ciombor","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-0612","authenticated-orcid":false,"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"issue":"1","key":"2024041017281310400_CIT0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2024041017281310400_CIT0002","first-page":"829","article-title":"Recent trends in squamous cell carcinoma of the anus incidence and mortality in the united states, 2001-2015","volume-title":"J Natl Cancer Inst","author":"Deshmukh","year":"2020"},{"issue":"2","key":"2024041017281310400_CIT0003","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"key":"2024041017281310400_CIT0004","first-page":"281","article-title":"Anal cancer incidence and survival: the surveilance, epidemiology, and end results experience, 1973-2000","volume-title":"Cancer","author":"Johnson","year":"2004"},{"key":"2024041017281310400_CIT0005","first-page":"776","article-title":"High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis","volume-title":"Eur J Cancer","author":"Baricevic","year":"2015"},{"key":"2024041017281310400_CIT0006","first-page":"1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume-title":"JAMA","author":"Ajani","year":"2008"},{"key":"2024041017281310400_CIT0007","first-page":"516","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume-title":"Lancet Oncol","author":"James","year":"2013"},{"key":"2024041017281310400_CIT0008","first-page":"11133","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume-title":"Oncotarget","author":"Eng","year":"2014"},{"issue":"22","key":"2024041017281310400_CIT0009","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024041017281310400_CIT0010","first-page":"124","article-title":"Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma","volume-title":"Radiat Oncol","author":"Thind","year":"2014"},{"issue":"15_suppl","key":"2024041017281310400_CIT0011","doi-asserted-by":"crossref","first-page":"TPS3614","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3614","article-title":"A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: a trial of the ECOG-ACRIN cancer research group (EA2176)","volume":"39","author":"Roth","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024041017281310400_CIT0012","first-page":"1036","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume-title":"Ann Oncol","author":"Ott","year":"2017"},{"key":"2024041017281310400_CIT0013","article-title":"Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation. [Internet]","volume-title":"J Clin Oncol","author":"Alvarez","year":"2023"},{"key":"2024041017281310400_CIT0014","first-page":"5767","article-title":"Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal squamous cell carcinoma","volume-title":"Clin Cancer Res","author":"Cabel","year":"2018"},{"issue":"10","key":"2024041017281310400_CIT0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2024041017281310400_CIT0016","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13059-014-0453-8","article-title":"Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine","volume":"15","author":"Hiley","year":"2014","journal-title":"Genome Biol"},{"key":"2024041017281310400_CIT0017","first-page":"1336","article-title":"Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes","volume-title":"Ann Oncol","author":"Chung","year":"2016"},{"key":"2024041017281310400_CIT0018","first-page":"1542","article-title":"Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal","volume-title":"Mol Cancer Res","author":"Morris","year":"2017"},{"issue":"40","key":"2024041017281310400_CIT0019","doi-asserted-by":"crossref","first-page":"65364","DOI":"10.18632\/oncotarget.11692","article-title":"Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA","volume":"7","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"2024041017281310400_CIT0020","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-17-0061","article-title":"Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer","volume":"16","author":"Chae","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2024041017281310400_CIT0021","first-page":"1399","article-title":"Matched whole-genome sequencing (WGS) and whole-exome sequencing (WES) of tumor tissue with circulating tumor DNA (ctDNA) analysis: complementary modalities in clinical practice","volume-title":"Cancers (Basel)","author":"Imperial","year":"2019"},{"issue":"16","key":"2024041017281310400_CIT0022","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1002\/cncr.33571","article-title":"High concordance of actionable genomic alterations identified between circulating tumor DNA\u2013based and tissue-based next-generation sequencing testing in advanced non\u2013small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program","volume":"127","author":"Park","year":"2021","journal-title":"Cancer"},{"key":"2024041017281310400_CIT0023","first-page":"2167","article-title":"Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing","volume-title":"J Cancer Res Clin Oncol","author":"Chang","year":"2018"},{"key":"2024041017281310400_CIT0024","first-page":"43594","article-title":"Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas","volume-title":"Oncotarget","author":"Smaglo","year":"2015"},{"issue":"10","key":"2024041017281310400_CIT0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Mart\u00ednez-Jim\u00e9nez","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2024041017281310400_CIT0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.20892\/j.issn.2095-3941.2016.0004","article-title":"Current practices and guidelines for clinical next-generation sequencing oncology testing","volume":"13","author":"Strom","year":"2016","journal-title":"Cancer Biol Med"},{"issue":"8","key":"2024041017281310400_CIT0027","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-19-0306","article-title":"Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer","volume":"26","author":"Pairawan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024041017281310400_CIT0028","first-page":"2488","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume-title":"N Engl J Med","author":"Jaiswal","year":"2014"},{"key":"2024041017281310400_CIT0029","first-page":"13261","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume-title":"Sci Rep","author":"Ettrich","year":"2019"},{"issue":"5","key":"2024041017281310400_CIT0030","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/PO.20.00532","article-title":"Clinical outcomes in non\u2013small-cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors and other targeted therapies based on tumor versus plasma genomic profiling","volume":"5","author":"Tran","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2024041017281310400_CIT0031","first-page":"2407","article-title":"Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH Trial (EAY131) subprotocol W","volume-title":"J Clin Oncol","author":"Chae","year":"2020"},{"issue":"10","key":"2024041017281310400_CIT0032","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1\u20134 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann Oncol"},{"key":"2024041017281310400_CIT0033","first-page":"272","article-title":"Targeted fibroblast growth factor receptor (FGFR) inhibition in recurrent, metastatic anal carcinoma: a case report","volume-title":"Clin Colorectal Cancer","author":"Miranda","year":"2022"},{"key":"2024041017281310400_CIT0034","first-page":"507","article-title":"Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review","volume-title":"BMC Cancer","author":"Mohyuddin","year":"2020"},{"issue":"3_suppl","key":"2024041017281310400_CIT0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS153","article-title":"MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)","volume":"39","author":"Strickler","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024041017281310400_CIT0036","first-page":"687","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume-title":"Lancet","author":"Bang","year":"2010"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/4\/e475\/57210435\/oyad326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/4\/e475\/57210435\/oyad326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T18:16:17Z","timestamp":1712772977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/4\/e475\/7476063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,16]]},"published-print":{"date-parts":[[2024,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad326","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2023,12,16]]}}}